PHBB.F Stock Overview
Provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 1/6 |
Pharmaron Beijing Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥1.93 |
52 Week High | CN¥2.25 |
52 Week Low | CN¥1.93 |
Beta | 0.65 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -14.22% |
Recent News & Updates
Recent updates
Shareholder Returns
PHBB.F | US Life Sciences | US Market | |
---|---|---|---|
7D | 0% | 2.8% | 2.2% |
1Y | n/a | 2.9% | 31.6% |
Return vs Industry: Insufficient data to determine how PHBB.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how PHBB.F performed against the US Market.
Price Volatility
PHBB.F volatility | |
---|---|
PHBB.F Average Weekly Movement | n/a |
Life Sciences Industry Average Movement | 8.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PHBB.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHBB.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 20,295 | Boliang Lou | www.pharmaron.com |
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vitro biology, DMPK, in vivo pharmacology, and compound management services; chemistry, manufacturing, and controls services. It also provides clinical development services, including integrated radio labelled science, clinical development, and clinical trial recruitment services; safety assessment, integrated drug discovery, and bioanalysis services; and biologics and cell and gene therapy services, comprising biologics laboratory, biologics CDMO, cell and gene therapy laboratory, and gene therapy CDMO services.
Pharmaron Beijing Co., Ltd. Fundamentals Summary
PHBB.F fundamental statistics | |
---|---|
Market cap | US$4.67b |
Earnings (TTM) | US$207.01m |
Revenue (TTM) | US$1.60b |
25.1x
P/E Ratio3.2x
P/S RatioIs PHBB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHBB.F income statement (TTM) | |
---|---|
Revenue | CN¥11.48b |
Cost of Revenue | CN¥7.47b |
Gross Profit | CN¥4.01b |
Other Expenses | CN¥2.53b |
Earnings | CN¥1.48b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
Earnings per share (EPS) | 0.83 |
Gross Margin | 34.94% |
Net Profit Margin | 12.92% |
Debt/Equity Ratio | 58.3% |
How did PHBB.F perform over the long term?
See historical performance and comparison